Equities research analysts at Citigroup began coverage on shares of Arsanis (NASDAQ:ASNS) in a research report issued on Monday. The firm set a “buy” rating and a $27.00 price target on the stock. Citigroup’s price target indicates a potential upside of 122.77% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. Cowen started coverage on shares of Arsanis in a research note on Monday. They set an “outperform” rating for the company. Piper Jaffray Companies started coverage on shares of Arsanis in a research note on Monday. They set an “overweight” rating and a $23.00 price objective for the company.

Arsanis (ASNS) opened at $12.12 on Monday. Arsanis has a 52-week low of $12.00 and a 52-week high of $19.73.

In other Arsanis news, major shareholder Polaris Venture Management Co. acquired 500,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was bought at an average cost of $10.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tillman U. Gerngross acquired 200,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were acquired at an average price of $10.00 per share, with a total value of $2,000,000.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/citigroup-initiates-coverage-on-arsanis-asns/1760648.html.

About Arsanis

Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.